CV09050101 mRNA vaccine (Curevac)

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameCV09050101 mRNA vaccine (Curevac)

Drug Alias NameCVGBMCV09050101CV-09050101

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineCell and gene therapy > Gene therapy > LNP

Mechanisms of ActionImmunostimulants

TargetsBrevican core proteinReceptor-type tyrosine-protein phosphatase zetaBaculoviral IAP repeat-containing protein 5 +[4]

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumNetherlandsGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCurevac Ag

China Registration ClassN/A

Develop Information

Active CompaniesCurevac Ag

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A